Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tactile Systems TechnologyFRA:3L3 +1.35%79 EV-to-EBITDA is 10.69 as of Aug. 19, 2026, which is 73% below its 10-year median of 40.02. GuruFocus rates FRA:3L3 with a GF Score™ of 79/100 and a GF Value™ of €16.48 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 513 Medical Devices & Instruments companies, Tactile Systems Technology ranks better than 65.5% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Tactile Systems Technology's enterprise value is €405.8 Mil.
Tactile Systems Technology's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €38.0 Mil. Therefore, Tactile Systems Technology's EV-to-EBITDA for today is 10.69.
The historical rank and industry rank for Tactile Systems Technology's EV-to-EBITDA or its related term are showing as below:
FRA:3L3'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -5448.1 Med: 40.02 Max: 232.48
Current: 10.61
During the past 13 years, the highest EV-to-EBITDA of Tactile Systems Technology was 232.48. The lowest was -5448.10. And the median was 40.02.
FRA:3L3's EV-to-EBITDA is ranked better than 65.5% of 513
companies
in the Medical Devices & Instruments industry
Industry Median: 14.77
vs FRA:3L3: 10.61
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Tactile Systems Technology (FRA:3L3) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Tactile Systems Technology's PE Ratio (TTM) for today is calculated as:
Tactile Systems Technology's share price for today is €21.00.
Tactile Systems Technology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.926.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:3L3 vs CBLL, CERS, CTKB: EV-to-EBITDA Comparison
For the Medical Devices subindustry, Tactile Systems Technology's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tactile Systems Technology EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Tactile Systems Technology's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Tactile Systems Technology's EV-to-EBITDA falls into.
Tactile Systems Technology's current Enterprise Value is €405.8 Mil.
Tactile Systems Technology's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €38.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tactile Systems Technology (FRA:3L3) has a EV-to-EBITDA of 10.69 as of Aug. 19, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Tactile Systems Technology. This is 73% below median its historical median of 40.02. According to the industry distribution chart, Tactile Systems Technology ranks #177 out of 513 companies in the Medical Devices & Instruments industry, placing it in the top 34.5%.
Is Tactile Systems Technology's EV-to-EBITDA too high?
Tactile Systems Technology's current EV-to-EBITDA of 10.69 is 73% below median its 10-year median of 40.02. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.77. Tactile Systems Technology's value of 10.69 is 27.6% below this industry median. Based on the distribution chart, Tactile Systems Technology ranks #177 out of 513 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Tactile Systems Technology has a GF Score™ of 79/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tactile Systems Technology's EV-to-EBITDA compare to CBLL and CERS?
According to the Medical Devices & Instruments industry distribution chart, Tactile Systems Technology ranks #177 out of 513 companies for EV-to-EBITDA. This puts Tactile Systems Technology in the upper half of its industry. The industry median EV-to-EBITDA is 14.77. Tactile Systems Technology's value of 10.69 is 27.6% below this benchmark. While the company's 10-year median is 40.02 vs. the industry median of 14.77, Tactile Systems Technology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.77, based on 513 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tactile Systems Technology's current EV-to-EBITDA of 10.69 is 27.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Tactile Systems Technology. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tactile Systems Technology's current EV-to-EBITDA is 10.69, which is 73% below median its own 10-year median of 40.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tactile Systems Technology stock overvalued right now?
Based on GuruFocus' analysis, Tactile Systems Technology (FRA:3L3) is currently considered Modestly Overvalued. The stock's GF Value™ is €16.48, compared to a current price of €21.00 — trading 27.4% above its estimated fair value. The current EV-to-EBITDA is 10.69, which is 73% below median its 10-year median of 40.02 and 27.6% below the Medical Devices & Instruments industry median of 14.77. Tactile Systems Technology's overall GF Score™ is 79/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Tactile Systems Technology (FRA:3L3), the current EV-to-EBITDA is 10.69 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tactile Systems Technology (FRA:3L3) Overvalued in 2026?
Based on GuruFocus' analysis, Tactile Systems Technology stock appears to be overvalued.
The current stock price of €21.00 is trading 27.4% above its estimated GF Value™ of €16.48.
GuruFocus considers Tactile Systems Technology to be Modestly Overvalued.
Key valuation signals for FRA:3L3:
EV-to-EBITDA: 10.69 (73% below median its 10-year median of 40.02)
GF Value™: €16.48 vs. price of €21.00 (27.4% above fair value)
Industry Position: 27.6% below the Medical Devices & Instruments median (#177 of 513)
No single metric tells the full story. See the FRA:3L3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tactile Systems Technology Inc is a medical technology company. The company is engaged in developing and providing medical devices for the treatment of chronic diseases. The firm's proprietary platform flexitouch system, provides a home-based solution for lymphedema patients. The entire system is another home solution for patients with chronic swelling and actitouch system for chronic venous insufficiency patients that may be worn throughout the day.
79GF Score
Get the complete analysis for FRA:3L3
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:3L3 has been successfully added to your 
